Association of Cerebral Small Vessel Disease With Gait and Balance Disorders

Chen Su, Xiaoyu Yang, Shuqi Wei and Renliang Zhao*
Department of Neurology, The Affiliated Hospital of Qingdao University, Qingdao, China

Cerebral small vessel disease (CSVD) is a common cerebrovascular disease and an important cause of gait and balance disorders. Gait and balance disorders can further lead to an increased risk of falls and a decreased quality of life. CSVD can damage gait and balance function by affecting cognitive function or directly disrupting motor pathways, and different CSVD imaging features have different characteristics of gait and balance impairment. In this article, the correlation between different imaging features of sporadic CSVD and gait and balance disorders has been reviewed as follows, which can provide beneficial help for standardized management of CSVD.

Keywords: gait and balance disorders, cerebrovascular disease, white matter hyperintensity, lacunar infarction, cerebral microbleeds, enlarged perivascular space, brain atrophy

INTRODUCTION

Cerebral small vessel disease (CSVD) is a pathological process of cerebral arterioles, capillaries, and venules caused by a variety of factors. CSVD appears on magnetic resonance imaging (MRI) as white matter hyperintensities (WMH), cerebral microbleeds (CMB), lacunar infarctions (LI), enlarged perivascular spaces (EPVS), and brain atrophy (Pantoni, 2010; Wardlaw et al., 2013a). Sporadic CSVD is closely correlated with age, with prevalence increasing from approximately 5% in people aged 50 to nearly 100% in people aged 90 (de Leeuw et al., 2001). CSVD is a major cause of cognitive impairment, dementia, and stroke, which is a huge burden on public health (Debette and Markus, 2010). Gait and balance disorders are the second most common problem in CSVD after cognitive impairment (Okroglic et al., 2010). Gait and balance disorders are common in older adults and can lead to falls and functional dependence, increasing the risk of hospitalization and death (van der Holst et al., 2016; Bower et al., 2019). A study conducted by Wei et al. (2017) showed that gait and balance function were independent predictors of the risk of falls in patients 1 month after stroke, suggesting that appropriate gait training may be one of the key factors in preventing falls in patients with stroke. We aim to assist the standardized management of CSVD by discussing the pathogenesis, diagnosis, and treatment of gait and balance disorders associated with sporadic CSVD. The mechanism of the association between sporadic CSVD and gait and balance disorders is summarized as follows (Figure 1).

CORRELATION BETWEEN CSVD AND GAIT AND BALANCE DISORDERS

Gait and balance are considered to be multisystem interactions, which suggests that clinical gait and balance problems may arise from different pathological mechanisms, such as attention,
The framework of the associated mechanisms between cerebral small vascular disease (CSVD) and gait and balance disorders. (1) White matter hyperintensities (WMH) can disrupt gait and balance by interfering with motion pathways and cortical thickness. (2) Lacunar infarctions (LI) impair gait and balance by interfering with cognition and motion pathways. (3) Cerebral microbleeds (CMB) affect gait and balance by damaging motion pathways. (4) Brain atrophy can disrupt gait and balance by damage to cognition, nuclei atrophy related to motion control, and cortex and white matter atrophy. (5) Enlarged perivascular spaces (EPVS) have shown no direct evidence to disrupt gait and balance. (6) CSVD can aggravate the impairment of gait and balance by affecting neurodegenerative diseases.

planning, visuospatial, and motor processes, and are closely related to executive function in the cognitive domain (Horak, 2006). The study of Cai et al. showed that gait disorders in elderly patients with CSVD are mediated by cognitive function impairment (Cai et al., 2021). Gait requires the supervision of cognitive function, especially executive function, and patients need the brain to allocate attention to control gait and balance. The decline in cognitive ability will damage their balance control ability (Yip et al., 2014; Cai et al., 2021). CSVD can cause extensive neural network damage by damaging important fiber bundles and loops, resulting in impaired visual, cognitive, sensory, and motor functions, especially in the frontal lobe, temporal lobe, basal ganglia, and other parts related to executive function, which will lead to a more obvious decline in executive function (Chao et al., 2009). Zhou et al. (2020) showed that gait and balance disorders in CSVD patients were related to the sensorimotor network and frontoparietal network as well as abnormalities in auxiliary motor areas. Other studies have shown that CSVD disrupts the cortex-striatum-globus pallidus-thalamic-cortical circuit, leading to depressive states, and poststroke depression also increases the risk of gait disorders (Wei et al., 2017; Rensma et al., 2018).

**Association of WMH With Gait and Balance**

WMH are a type of sporadic small vascular disease, and axon loss and demyelination are the causes of WMH, which may be the result of chronic ischemia caused by CSVD (Staszewski et al., 2015). It is also believed that hypoperfusion is related to cerebral vascular autoregulation changes or blood–brain barrier dysfunction (Simpson et al., 2007), inflammation, and amyloid vascular disease (Gouw et al., 2011). 20% of WMH can be found in adults in their 60s and up to 94% in those in their 80s (Garde et al., 2000). On imaging, WMH show high signals on T2-weighted sequences and equal signals or low signals on T1-weighted sequences (Fujishima et al., 2014). WMH can be divided into periventricular white matter hyperintensities (PVWMH) and deep white matter hyperintensities (DWMH). Traditional imaging techniques or semiautomated techniques are used to measure the volume of white matter lesions. New methods, such as magnetic resonance diffusion tensor imaging.
imaging (DTI) and voxel-based morphology analysis (VBM), can also be used to analyze the integrity of white matter. One study confirmed that WMH scores and total CSVD scores were associated with poorer gait speed and body balance in healthy older adults (Pinter et al., 2017). In patients with vascular cognitive impairment, gait and balance disorders were mainly characterized by reduced arm swing, stoop, reduced step length, and broad base gait, which were only associated with PVWMH volume and white matter integrity but not with other radiological markers of CSVD (Kim et al., 2016). The LADIS study confirmed that the severity of WMH in the deep frontal lobe and PVWMH significantly impaired balance function in the elderly population, which supported the hypothesis that the disruption of motor circuits in the subfrontal cortex caused balance disorders (Blahak et al., 2009). DTI provides an indicator of the internal microstructure integrity of neural networks and can reflect the loss of white matter integrity (Pasi et al., 2016). A study using DTI found that stride length decline was associated with white matter atrophy and an increase in mean white matter radial diffusivity and mean diffusivity and a decrease in mean fractional anisotropy (FA), with the strongest association found in the corpus callosum and radial crown fibers (van der Holst et al., 2017). The corpus callosum white matter connects the frontal, parietal, and occipital cortices, and fibers from these areas reverse into the radiative crown, which contains projective fibers involved in motor pathways and thus plays a key role in motor function (Jang, 2009). In another study using DTI, total white matter lesions in CADASIL patients only affected stride length on a single task (Finsterwalder et al., 2019). PVWMH are more likely to cause cognitive impairment than DWMH and executive dysfunction due to the concentration of a large number of neurons and fibers related to learning, memory, and cognition, and the white matter bundle crossing periventricular white matter is denser (Onteddu et al., 2015). White matter injury, especially DWMH, also increased the likelihood of poststroke depression (Fujishima et al., 2014). However, no studies have directly shown that WMH affect gait independently by affecting cognition or depression. A study using the VBM technique showed that the bilateral frontal and periventricular white matter corresponding to the major anterior projection fibers (thalamic radiation, cortical motor tracts) and adjacent association fibers (corpus callosum, superior fronto-occipital fasciculus, short association fibers) showed the greatest correlation with poor gait (Srikanth et al., 2010). This suggested that white matter injury can lead to an age-related decline in gait and trunk balance stability by disconnecting the motor network composed of these fiber bundles. Another study using the VBM technique showed that fibers associated with gait and balance disorders crossed periventricular white matter more densely than deep white matter and that the cortical regions connected by these fibers overlapped with cortical thinning regions associated with gait performance. The mediation analysis showed that PVWMH mediated gait disorders through average FA or cortical thickness (Kim et al., 2016). We can determine that WMH affect gait and balance through the following mechanisms: (1) direct damage to motion-related neural networks; and (2) destruction of white matter integrity leading to thinning of the related cortex.

**Association of LI With Gait and Balance**

LI, which account for 25% of all acute ischemic strokes, are radiographically characterized by round, oval, or tubular infarcts with a diameter <20 mm, hypersignal on diffusion weighted imaging (DWI), hypersignal on T2-weighted and fluid-attenuated inversion recovery (FLAIR), and hypersignal on T1. They usually occur in the basal ganglia, inner sac, thalamus, corona radialis, centrum semiovale, and brain stem (Wardlaw et al., 2013a; Li et al., 2018). LI are usually silent and found in 20%–50% of older adults (Vermeer et al., 2007). While many LI lack acute symptoms, their presence in large numbers has been associated with dementia, cognitive impairment, gait impairment, and an increased risk of stroke (Shi and Wardlaw, 2016). A study of healthy community populations showed that LI were associated with slower gait speed and balance disorders (Smith et al., 2015). LI located in the frontal lobe and thalamus were associated with lower gait speed, and stride length was more sensitive than stride speed as an outcome indicator (de Laat et al., 2010), which can be related to the involvement of the frontal-basal ganglia-thalamic-cortex circuit in gait motor function (Bazner et al., 2000).

LI are an important predictor of cognitive impairment in CSVD with significant spatial distribution characteristics, especially the anterior medial thalamus LI, which are associated with impaired information processing speed and may lead to cognitive impairment by disrupting connections to the prefrontal cortex (Benjamin et al., 2014, 2018). A study linked LI in the frontal lobe to motoric cognitive risk syndrome (MCR; Wang et al., 2016). MCR is a predementia syndrome characterized by cognitive complaints and slow gait in elderly people without dementia (Verghese et al., 2014). LI in the frontal lobe may cause MCR by disrupting neural networks based on the frontal lobe that assist memory and gait function (Takakusaki, 2013). Studies have shown that LI interact with WMH, and the presence of LI can aggravate the impairment of gait and postural stability in patients with WMH, which may be the result of a higher brain injury load leading to more easily impaired functions (Choi et al., 2012). In addition, deep white matter LI are also associated with the severity and fluctuation of depressive symptoms, which may be related to the disruption of the emotional circuit (Grool et al., 2013). However, whether LI can affect gait and balance by affecting WMH or depression is unclear.

In conclusion, LI can affect gait and balance function through the following two mechanisms: (1) direct damage to motor pathways, such as the frontal lobe and basal ganglia; and (2) MCR by influencing cognition.

**Association of CMB With Gait and Balance**

CMB are circular or elliptical uniform low signal regions with a clear boundary and a diameter of 2–5 mm and a maximum of 10 mm on gradient recalled echo (GRE) and susceptibility weighted imaging (SWI). CMB have been shown to occur in 23.5% of healthy elderly populations (Pasi et al., 2017). CMB were found in 17.8% of patients aged 60–69 years and 38.3% of patients aged over 80 years, with the prevalence fluctuating by approximately 5% (Cordonnier et al., 2007; Ding et al., 2015). The CMB has the same spatial distribution characteristics as LI.
and is mostly located at the corticocortical subcortical junction and deep gray or white matter in the hemispheres, brainstem, and cerebellum (Wardlaw et al., 2013b). Currently, there are few studies on the association between CMB and gait and balance disorders. For instance, de Laat et al. (2011) demonstrated for the first time that CMB located in the basal ganglia, thalamus, and frontal lobe were associated with gait and balance disorders in elderly patients without dementia, independent of other coexisting CSVD markers, and these regions were associated with gait control. Gait and balance disorders were mainly represented by shorter stride length and decreased trunk balance (de Laat et al., 2011). This suggested that CMB can directly damage the site and thus disrupt motor pathways. However, most studies since then have shown no direct link between CMB and gait and balance. A cross-sectional study in Japan showed that short standing time on one leg was independently associated with the number of lacunes and CMB and was associated with decreased cognitive function (Tabara et al., 2015). The CMB is an important factor in the decline in cognitive function (Lei et al., 2013). The presence of CMB in the frontal and temporal lobes may be associated with decreased nonverbal memory, visual-spatial memory, and psychomotor speed (van Norden et al., 2011). The existence of the basal ganglia CMB may be associated with attention and computing ability, and the existence of the thalamus CMB may be associated with independent overall cognition (Yakushiji et al., 2008). Whether CMB can indirectly lead to gait and balance disorders by influencing cognition remains to be further studied. CMB interact with WMH, and similar to LI, the presence of CMB also increases the negative effects of WMH on gait and balance (Choi et al., 2012). However, whether CMB can affect gait and balance through WMH is unknown.

As discussed above, CMB can affect gait and balance through direct damage to motor pathways associated with gait and balance control.

Association of Brain Atrophy With Gait and Balance

Brain atrophy is characterized by a reduced brain volume on CT or MRI and is unrelated to local volume reduction caused by trauma or infarction. Atrophy is characterized by enlarged ventricles and widened sulci gyrus (Muller et al., 2011; Wardlaw et al., 2013b). Many imaging studies have reported the presence and severity of CSVD associated with brain atrophy, including global, cortical, subcortical, central (enlarged ventricles and basal ganglia), midbrain, and hippocampal atrophy (Appelman et al., 2009, 2010; Aribisala et al., 2013). A study of CSVD and gait disorders showed that gait scores were associated with thinning of the bilateral motor area, premotor area, dorsolateral prefrontal area, anterior cingulate area, and lateral temporoparietal occipital cortex. Thinning of the mean cortex was associated with gait severity, stooped posture, magnetic gait, small step, shuffling, and broad based gait (Kim et al., 2016). Brain white matter atrophy is associated with decreased gait speed, step length, and step frequency in community residents aged 60–86 years, hippocampal atrophy is associated with decreased gait speed and step length, and total gray matter atrophy is associated with decreased gait rhythm in patients with cerebral infarction (Callisaya et al., 2013). Basal ganglia LI, caudate nucleus atrophy, and global brain atrophy are associated with bradykinesia and balance disorders in healthy subjects aged 45–84 years (Camarda et al., 2018). Brain atrophy predicts cognitive decline, hippocampal volume correlates with changes in executive function performance, and frontal and temporal gray matter predicts changes in the verbal episodic memory performance (Aljondi et al., 2019). A study using PET technology found that reduced glucose metabolism in the posterior cingulate cortex and primary sensorimotor cortex was associated with lower gait performance (reduced step speed, reduced stride frequency) and executive function, suggesting that gait control and executive function may share the same neural substrate (Sakurai et al., 2017). Mediation analysis confirmed that thalamic atrophy mediated the effect of CSVD on walking speed in elderly people, and CSVD affected walking performance by destroying thalamic integrity (Su et al., 2018).

In summary, brain atrophy can affect gait and balance through the following two mechanisms: (1) atrophy of the cortex, white matter, and nucleus; and (2) reduced executive function.

Association of EPVS With Gait and Balance

Perivascular spaces (PVS) are formed when the arterioles and venules pass through the brain parenchyma from the subarachnoid space. PVS are important drainage channels for the interstitial fluid of the brain. When the PVS is enlarged, EPVS are seen as punctate or linear high intensity on T2-weighted MRI, and diameters are usually no more than 3 mm (Wardlaw et al., 2013b; Potter et al., 2015). The incidence of EPVS was 79.9%, and the incidence of EPVS in the basal ganglia was slightly higher than that in white matter (Zhang et al., 2014). EPVS are generally associated with other morphological features of CSVD, such as WMH and LI, but not with brain atrophy (Kwee and Kwee, 2007; Zhu et al., 2010). At present, there are few reports on EPVS related to gait and balance, and only a few studies have reported the relationship between EPVS and Parkinson’s disease and Alzheimer’s disease populations. Basal ganglia EPVS were related to the poor prognosis of Parkinson’s disease motor symptoms and the tremor score of Parkinson’s disease patients (Wan et al., 2019; Chung et al., 2021). Basal ganglia EPVS were also a biomarker of CSVD in patients with senile dementia and higher in patients with vascular dementia than in Alzheimer’s disease and healthy volunteers. Poor scores of nonverbal reasoning and global visuospatial tasks were significantly associated with EPVS load in healthy people (Hansen et al., 2015).

At present, the relationship between EPVS and gait and balance function is unclear and requires further study.

Association of Total CSVD Burden With Gait and Balance

The above explores the relationship between individual imaging markers of CSVD and gait and balance. Total CSVD burden (0–4 points): ≥ 1 cavity is one point; DWMH score is 2 or 3 or PVWMH score is 3 points; moderate to severe EPVS (2–4 points) was scored as one point; CMB ≥ 1 score is 1 point (Wardlaw et al., 2013b; Staals et al., 2015). A growing body of research shows
that summarizing the total CSVD load of individual markers of CDVD on the load scale may better reflect the overall effect of CSVD on the brain (Staals et al., 2015; Pinter et al., 2017). However, there have been few studies on the effect of the total burden of CSVD on gait and balance. A study of elderly subjects with vascular risk factors showed that concurrent gait function as measured according to the Parkinson's disease assessment scale was associated with the overall CSVD burden. This is the first study to examine concurrent gait function and overall CSVD burden, although the CSVD burden score does not include EPVS (Hatate et al., 2016). A study of 678 elderly healthy subjects in the community found that the total WMH and CSVD scores were independently associated with slower gait speeds in the 6-meter walk test (Pinter et al., 2017). The results of this cross-sectional study need to be validated by large prospective studies. However, in a recent prospective study of total CSVD burden and minor stroke patients, CSVD scores at 3 years of follow-up were not associated with objective gait and balance disorders but only with subjective mobility disorders (Loos et al., 2018). The relationship between the overall burden of CSVD and gait and balance needs further study.

CSVD AND NEURODEGENERATIVE DISEASES

There is growing evidence of an interaction between CSVD and neurodegenerative diseases, and we explore the effects of both on gait and balance below.

Parkinson’s Disease

Parkinson’s disease (PD) is a neurodegenerative disorder that causes decreased motor capacity and nonmotor symptoms (Pfeiffer, 2016). PD and CSVD are both age-related diseases (De Virgilio et al., 2016), and a large number of relevant studies in recent years have continued to confirm the prevalence of concomitant CSVD in patients with PD. The study found that 76% of patients with PD had concomitant CSVD (Song et al., 2017). PD and CSVD have a common pathological inflammatory response, and studies have confirmed that CSVD can participate in the development of PD through an inflammatory response (Lenart et al., 2016; La Vitola et al., 2018). Bohnen et al. (2011) found that the severity of WMH was positively correlated with the axial motor symptom score and bradycardia score of patients with PD. Recent studies have also confirmed that the presence of WMH is an independent risk factor for postural gait disorders in patients with PD (Wan et al., 2019). Another study found that in patients with PD, the postural instability disorder type with WMH was more severe than the tremor type, which further confirmed that WMH were associated with axial dyskinesia of PD (Malek et al., 2016). It has been suggested that WMH, especially frontal white matter lesions, may disrupt the integrity of the frontal-striatal neural circuit and the frontal parietal circuit, thereby aggravating the damage to axial motor function in patients with PD (Lee et al., 2009). There are few studies on the correlation between LI and CMB and motor symptoms in PD patients. A cross-sectional study conducted by Zhang et al. (2016) showed that patients with PD who had asymptomatic LI in the striatum had severe disruption of substantia nigra structures. The study suggests that striatal LI in patients with PD may disrupt fibrous bundles in the striatum-nigra loop, which in turn affects the severity of motor symptoms in patients with PD. A cross-sectional study was grouped according to whether the subjects had CMB, and the results suggested that CMB may have no effect on motor symptoms in patients with PD (Kim et al., 2015).

Alzheimer’s Disease

Alzheimer’s disease (AD) is a progressive neurodegenerative disease of the brain in which clinical symptoms gradually develop from cognitive impairment to dementia (Vinters, 2015). It is well known that adult patients with AD have balance and gait deficits compared to non-AD patients (Kato-Narita et al., 2011; Suttanon et al., 2012; Gras et al., 2015). As cognitive dysfunction progresses, physical function in patients with AD declines, and deficits in balance and gait become more pronounced. This is associated with impaired executive function in patients with AD (Scherder et al., 2007). Many studies have shown that CSVD increases the risk of developing AD, and pathological signs of AD can also be present in both vascular dementia and CSVD (Henry-Feugeas, 2008). Although the underlying mechanism of CSVD-induced AD pathology is unclear, it could be explained by myelin fibrosis degeneration and neuronal death due to chronic cerebral hypoperfusion or blood–brain barrier (BBB) disruption from CSVD (Pantoni, 2010; Kim H. W. et al., 2020). WMH has been widely accepted in imaging associations with aging and AD (Chen et al., 2011). For example, a longitudinal study showed that a high burden of WMH was associated with an increased risk of developing AD over a 5-year follow-up period (Ye et al., 2019). One cohort study showed that overall WMH load was associated with AD risk factors in subjects whose cognitive function was not impaired. The main drivers of this association are age and high blood pressure (Salvado et al., 2019). The role of CMB and LI in AD is unclear. A cross-sectional study found that CMB was associated with vascular burden and the diagnosis of AD (Caballero et al., 2020). A meta-analysis showed that CMB did not affect the course of AD (Liu et al., 2018). One cross-sectional study showed that elevated levels of LI were associated with increased levels of Aβ42 in vascular dementia and decreased levels of Tau in AD (Kester et al., 2014). Microinfarction is closely related to AD, and the number of microinfarcts is related to overall cognitive ability (van Rooden et al., 2014). Current studies do not support the role of EPVS in the early pathogenesis of AD (Gertje et al., 2021). Brain atrophy is the most important imaging morphological feature of AD (Guo et al., 2014), but the link between cerebral atrophy in the context of CSVD and AD remains unclear.

Multiple Sclerosis

Multiple sclerosis (MS) is a chronic inflammatory demyelinating disorder of the central nervous system in which neurodegeneration leads to long-term disability (Lassmann et al., 2007). MS leads to gait and balance disturbances and falls (Chee et al., 2021). Age is a major determinant of MS progression, onset, and disability (Tutuncu et al., 2013). CSVD is a common age-related cerebrovascular disease (de Leeuw et al., 2001). An
The SPPB is a rapid, objective three-part physical function test that provides a comprehensive indicator of walking speed, standing balance, and sitting performance. It has good predictive validity and broad clinical applicability. It includes a normal walking speed of more than 4 m, five sit-stand tests, and a balance test. The score of each task is four points, and the scores of the three tests are added to obtain a total, with the maximum value being 12 and the minimum value being 0. The higher the total score is, the higher the functional level is (Guralnik et al., 2000; Perera et al., 2006). The SPPB has been shown to be predictive of adverse outcomes, including all-cause mortality, disability, and hospitalization (Volpato et al., 2011; Minneci et al., 2015; Pavadini et al., 2016), and SPPB scores have been shown to be independently associated with falls among hospitalized patients and elderly community residents (Lauretani et al., 2019; Welch et al., 2021). The SPPB has been primarily used to test and measure activity levels in the recovered population, but it cannot effectively measure physical performance indicators in young people with good motor function (Treacy and Hassett, 2018).

**TUG**

The TUG test is a reliable and effective rapid measurement method for evaluating athletic ability and quantifying athletic performance. This test records the time it takes subjects to sit back down after completing a 3-m walk and returning to the armchair, involving the movement speed and trunk balance (Wu et al., 2019). The TUG test has been shown to have a good correlation with the BBS (Podsiadlo and Richardson, 1991), but it is more convenient and commonly used to assess senior functional activities after stroke (Chan et al., 2017). TUG can assess realistic mobility, including potential falls (Bischoff et al., 2003). However, the TUG test has some limitations. It does not address the problem of decreased motor performance when performing cognitive and motor tasks at the same time (Plummer et al., 2013). The latest meta-analysis suggests that TUG should not be used alone to predict fall risk (Park, 2018).

**BBS**

The BBS consists of 14 items, each of which is scored from 0 (unable to perform) to 4 (normal execution) on a scale of 0–56, involving functional balance control, including transfer, steering, and walking, with a higher score indicating better balance (Berg et al., 1992). BBS is a reliable, effective, and widely used tool. It does not require people to be able to walk or stand independently. It is often used to evaluate the body balance ability of people with various physical conditions and disabilities, such as poststroke patients (Moon et al., 2017; Ursin et al., 2019), and the BBS can also predict the loss of important activities in daily life (Wennie Huang et al., 2010). However, BBS also has limitations. The BBS cannot measure gait quality and walking speed and is not suitable for screening patients under 75 years old (Downs, 2015). The evidence supporting the use of BBS to predict falls is insufficient, and it should not be used solely to determine the risk of falls in the elderly (Lima et al., 2018).
**DIAGNOSIS AND TREATMENT**

Gait and balance instability are important factors that cause falls in older adults (Wei et al., 2017; Bower et al., 2019), so screening out patients with CSVD with impaired gait and balance function and intervening with pharmacological and nonpharmacological interventions is important to improve the prognosis of CSVD.

**Diagnosis and Identification**

Walking speed is a very meaningful parameter for assessing the health of older adults, and if a person’s spontaneous walking speed is below 0.6 m/s, it is considered problematic (Panzer et al., 2011; Studenski et al., 2011). A total TMT score <19, BBS scores < 40 (Muir et al., 2008), and TUG ≥ 13.5 s (Clemson et al., 2015) indicate a higher risk of falling. A simple balance test, such as recording the time spent standing on one leg or in tandem, can also be used to identify CSVD patients at risk of falling early and assess their balance function (Jahn et al., 2015). Gait degradation under dual-task requirements is typical of gait disorders with cortical and subcortical involvement. Setting up dual tasks can catch defects at an early stage and suggest preventive measures such as increasing physical activity by increasing daily walking distance (Montero-Odasso et al., 2012). Subjective visual vertical tests are helpful in patients with unstable gait and a tendency to fall and are simple to perform (“bucket test”; Jahn et al., 2015).

**Rehabilitation Therapy**

In patients with impaired gait and balance, early rehabilitation is necessary. Traditional gait training methods include one-legged weight-bearing, the center of gravity shifting, stepping and hip stretching training, using the affected limb to go up and down stairs, walking laterally, and walking in place (Brock et al., 2011). Balance training included standing on one leg, walking in a straight line, throwing and catching the ball, standing in front of the mirror and being pushed in different directions by the therapist, and moving the body’s center of gravity forward, backward, sideways, and obliquely when the eyes were open and closed (Chung et al., 2014). The pro-kin system is a new visual feedback balance training method. The combination of pro-Kin system and conventional rehabilitation therapy can improve the gait and balance function of CSVD patients without obvious cognitive impairment better than traditional rehabilitation training (You et al., 2017; Zhao et al., 2019). In addition to physical exercises such as walking, people can also try exercise cognitive training such as tai chi and Dalcroze music pedagogy to improve the executive function of the elderly (Jahn et al., 2015).

**Treatment of CSVD**

Blood pressure is the most important controllable risk factor for CSVD. Intensive antihypertensive therapy can reduce the progression of WMH but the effect on brain atrophy is unclear (van Middelaar et al., 2018; Su et al., 2021). Intensive blood pressure lowering reduced the recurrence of stroke in patients with LI through a multicenter clinical trial called SPS3 (SPS3 Study Group et al., 2013). A more aggressive antihypertensive regimen may be justified, but too low a blood pressure carries the risk of cognitive impairment (Webb et al., 2010). Blood pressure variability is associated with WMH, CMB, EPVS, and total CSVD burden and may also lead to a poor prognosis. Therefore, reducing ambulatory blood pressure variability is important for the control of CSVD (Chen et al., 2019; Zhang et al., 2019a).

Patients who received intravenous r-tPA had a better neurological prognosis than those who received a placebo in LI (Mok and Kim, 2015). The presence of CMB and WMH increases the risk of symptomatic cerebral hemorrhage and poor prognosis, but patients still have a net benefit (Charidimou et al., 2016). The benefits and risks of intravenous thrombolysis in patients with CSVD need to be assessed individually to minimize the occurrence of cerebral hemorrhage and poor prognosis after thrombolysis in ischemic stroke.

For antiplatelet therapy, refer to the 2018 American Heart Association/American Stroke Association published guidelines for the early management of patients with acute ischemic stroke (Powers et al., 2019). Given the bidirectional nature of CSVD with both ischemia and bleeding risk, an assessment of treatment benefits and bleeding risk should be performed. Antiplatelet agents should be used with caution in patients with severe WMH and a large number of CMB. In patients with severe WMH and multiple CMB, cilostazol may be a safer option compared to aspirin and clopidogrel (Kim B. J. et al., 2020).

Statins have been shown to lower lipids, reduce oxidative stress and protect the vascular endothelium (Sander et al., 2005; Erdos et al., 2006), which may reduce the risk of stroke recurrence including ischemic stroke due to CSVD (Amarenco et al., 2009). Studies have shown that the application of statins can reduce the progression of WMH and the decline in cognitive function (Xiong et al., 2014). However, in patients with severe CSVD, high doses of statin are associated with an increased risk of a cerebral hemorrhage (Amarenco et al., 2009).

Daily B vitamins can lower homocysteine and thus may reduce WMH volume progression in patients with severe CSVD (Cavaleri et al., 2012). In addition, vitamin E tocotrienols slow the progression of WMH in subjects with brain white matter injury (Gopalan et al., 2014). Prevention and treatment strategies for CMB should target cerebral microvascular endothelium and function, blood-brain barrier, and neuroinflammation, such as endothelin antagonists, peroxisome proliferator-activated receptor-agonists, and neurotrophic factors (Nagasawa et al., 2014).

**Therapy for Cognition and Depression**

CSVD-associated cognitive dysfunction is an important subtype of vascular cognitive dysfunction and is one of the common causes of vascular dementia. There is some degree of overlap in the neuropathology of AD and vascular dementia, and cholinergic insufficiency may lead to vascular cognitive impairment (Roman and Kalaria, 2006). Various drugs, including donepezil and galantamine, have shown modest cognitive benefits in patients with vascular dementia. However, the benefits of other drugs, such as rivastigmine, memantine, nimodipine, piracetam, and herbal remedies, remain unclear (Faroq et al., 2017). Large randomized controlled trials have shown benefits in improving cognitive function in patients...
with mild to moderate vascular cognitive impairment at 24 weeks, and patients tolerate donepezil well (Goldsmith and Scott, 2003; Malouf and Birks, 2004). Nevertheless, in patients with CADASIL alone, donepezil did not significantly improve overall cognitive function (Dichgans et al., 2008). After 6 months of galantamine use, patients with mild to moderate cognitive impairment with AD and vascular dementia had significant improvements in cognitive function, but the side effects were significant (Erlkinjuntti et al., 2002; Auchus et al., 2007). There are also small sample studies that have found that antihypertensive drugs, statins, and nimodipine drugs may have some effect on CSVD-related cognitive impairment, but more large randomized controlled trials are needed to confirm this (Zhang et al., 2019b; Zhang J. et al., 2019). Patients with vascular depression responded poorly to common antidepressants, and the response rate of combination therapy with citalopram and methylphenidate was higher than that of the drug alone. This treatment also leads to improved function (Lavretsky et al., 2015; Smith et al., 2021). In elderly patients with depression and cognitive impairment, the combined use of antidepressants and donepezil had a temporary positive effect on cognitive function but increases the risk of recurrence (Reynolds et al., 2011).

**DISCUSSION**

In conclusion, exploring the correlation between CSVD and gait and balance disorders is of great clinical significance for the diagnosis and treatment of gait and balance disorders and the prevention of falls. CSVD is a disease in which multiple pathological changes can coexist, and its influence on gait and balance function is not caused by a single factor but may be the result of the joint action of multiple factors. In addition, imaging features of different CSVD and injury of different parts may lead to different characteristics and mechanisms of gait and balance injury but there may be overlap between them. And different small vascular diseases may also affect each other. In general, CSVD can affect gait and balance by affecting cognitive function, disrupting gait structures associated with balance control, influencing depressive states, and interactions. Rehabilitation and medication may play a role in gait and balance disorders.

Currently, most studies on CSVD and gait and balance disorders are cross-sectional studies or retrospective studies, and more prospective studies with large samples are needed in the future to further clarify the correlation between the two. In terms of the crowd, future studies should stratify patients with different causes and severity of the disease, such as the mild stroke population (Loos et al., 2018). The application of advanced imaging technology, such as VBM technology and DTI technology, can be a more accurate and comprehensive evaluation of the imaging appearances of CSVD, to clarify the role of CSVD in different brain diseases. As for the evaluation methods of gait and balance function, new measurement methods such as electronic sensors should be applied in gait and balance evaluation in the future, so as to obtain a more real and comprehensive evaluation and reduce the results bias caused by different test methods. Regarding the treatment of CSVD-related gait and balance disorders, future large-scale randomized controlled trials are needed to determine the direct effects of medication or rehabilitation on gait and balance function. The mechanisms of CSVD affecting gait and balance need to be further clarified, so as to provide more perspectives for the prevention and treatment of gait and balance disorders.

**AUTHOR CONTRIBUTIONS**

RZ planned the study. CS, XY, and SW analyzed the data and edited the manuscript. CS wrote the manuscript. All authors contributed to the article and approved the submitted version.

**REFERENCES**

Aljondri, R., Szeoce, C., Steward, C., Yates, P., and Desmond, P. (2019). A decade of changes in brain volume and cognition. *Brain Imaging Behav.* 13, 554–563. doi: 10.1007/s11682-018-9887-z

Alvarez, I., Latorre, J., Aguilar, M., Pastor, P., and Llorens, R. (2020). Validity and sensitivity of instrumented postural and gait assessment using low-cost devices in Parkinson’s disease. *J. Neuroeng. Rehabil.* 17:149. doi: 10.1186/s12984-020-00770-7

Amarenco, P., Benavente, O., Goldstein, L. B., Callahan, A., 3rd, Sillesen, H., Hennerici, M. G., et al. (2009). Results of the stroke prevention by aggressive reduction in cholesterol levels (SPARCL) trial by stroke subtypes. *Stroke* 40, 1405–1409. doi: 10.1161/STROKEAHA.108.534107

Appelman, A. P., Exalto, L. G., van der Graaf, Y., Biessels, G. J., Mali, W. P., and Geerlings, M. I. (2009). White matter lesions and brain atrophy: more than shared risk factors? A systematic review. *Cerebrovasc. Dis.* 28, 227–242. doi: 10.1159/000226774

Appelman, A. P., Vincken, K. L., van der Graaf, Y., Vlek, A. L., Witkamp, T. D., Mali, W. P., et al. (2010). White matter lesions and lacunar infarcts are independently and differently associated with brain atrophy: the SMART-MR study. *Cerebrovasc. Dis.* 29, 28–35. doi: 10.1159/000255971

Aribisala, B. S., Valdes Hernandez, M. C., Royle, N. A., Morris, Z., Munoz Maniega, S., Bastin, M. E., et al. (2013). Brain atrophy associations with white matter lesions in the ageing brain: the Lothian Birth Cohort 1936. *Eur. Radiol.* 23, 1084–1092. doi: 10.1007/s00338-012-2677-x

Auchus, A. P., Brashear, H. R., Salloway, S., Korczyk, A. D., De Deyn, P. P., Gassmann-Mayer, C., et al. (2007). Galantamine treatment of vascular dementia: a randomized trial. *Neurology* 69, 448–458. doi: 10.1212/01.wnl.000026625.31615.f6

Bazner, H., Oster, M., Daffertshofer, M., and Hennerici, M. (2000). Assessment of gait in subcortical vascular encephalopathy by computerized analysis: a cross-sectional and longitudinal study. *J. Neurol.* 247, 841–849. doi: 10.1007/s004150070070

Benjamin, P., Lawrence, A. J., Lambert, C., Patel, B., Chung, A. W., MacKinnon, A. D., et al. (2014). Strategic lacunes and their relationship to cognitive impairment in cerebral small vessel disease. *NeuroImage Clin.* 4, 828–837. doi: 10.1016/j.nicl.2014.05.009

Benjamin, P., Trippier, S., Lawrence, A. J., Lambert, C., Zeeustraten, E., Williams, O. A., et al. (2018). Lacunar infarcts, but not perivascular spaces, are predictors of cognitive decline in cerebral small-vessel disease. *Stroke* 49, 586–593. doi: 10.1161/STROKEAHA.117.017526

Berg, K. O., Wood-Dauphinee, S. L., Williams, J. I., and Maki, B. (1992). Measuring balance in the elderly: validation of an instrument. *Can. J. Public Health* 83, S7–S11.

Bischoff, H. A., Stahelin, H. B., Monsch, A. U., Iversen, M. D., Weyh, A., von Dechend, M., et al. (2003). Identifying a cut-off point for normal
mobility: a comparison of the timed ‘up and go’ test in community-dwelling and institutionalised elderly women. *Age Ageing* 32, 315–320. doi: 10.1093/ageing/afj139

Blahak, C., Baenziger, H., Pantoni, L., Poggesi, A., Chabrier, H., Erkinjuntti, T., et al. (2009). Deep frontal and periventricular age related white matter changes but not basal ganglia and infratentorial hyperintensities are associated with falls: cross sectional results from the LADIS study. *J. Neurol. Neurosurg. Psychiatry* 80, 608–613. doi: 10.1136/jnnp.2008.154633

Bohnen, N. I., Muller, M. L., Zarzhevsky, N., Koeppe, R. A., Bogan, C. W., Kilbourn, M. R., et al. (2011). Leukoaraiosis, nigrostriatal denervation and motor symptoms in Parkinson’s disease. *Brain* 134, 2358–2365. doi: 10.1093/brain/awr119

Bower, K., Thilagarajah, S., Pua, Y. H., Williams, G., Tan, D., Mentibay, B., et al. (2019). Dynamic balance and instrumented gait variables are independent predictors of falls following stroke. *J. Neuroeng. Rehabil.* 16:13. doi: 10.1186/s12984-018-0478-4

Brock, K., Haase, G., Rothacher, G., and Cotton, S. (2011). Does physiotherapy based on the Bobath concept, in conjunction with a task practice, achieve greater improvement in walking ability in people with stroke compared to physiotherapy focused on structured task practice alone?: A pilot randomized controlled trial. *Clin. Rehabil.* 25, 903–912. doi: 10.1177/0269215511406557

Brown, R. B., Traylor, M., Burgess, S., Sawyer, S., and Markus, H. S. (2019). Do cerebral small vessel disease and multiple sclerosis share common mechanisms of white matter injury? *Stroke* 50, 1968–1972. doi: 10.1161/STROKEAHA.118.022469

Caballero, M. A. A., Song, Z., Rubinski, A., Duering, M., Dichgans, M., Park, D. C., et al. (2020). Age-dependent amyloid deposition is associated with white matter alterations in cognitively normal adults during the adult life span. *Alzheimers Dement.* 16, 651–661. doi: 10.1016/j.alz.2019.08.002

Cai, M., Jacob, M. A., Norris, D. G., Duering, M., de Leeuw, F. E., and Brown, R. B., Traylor, M., Burgess, S., Sawcer, S., and Markus, H. S. (2019). Do cerebral small vessel disease and multiple sclerosis share common mechanisms of white matter injury? *Stroke* 50, 1968–1972. doi: 10.1161/STROKEAHA.118.022469

Charidimou, A., Pasi, M., Fiorelli, M., Shams, S., von Kummer, R., Pantoni, L., et al. (2017). Reliability and validity of the timed up and go test with a motor task in people with chronic stroke. *Arch. Phys. Med. Rehabil.* 98, 2213–2220. doi: 10.1016/j.apmr.2017.03.008

Chen, X., Zhu, Y., Geng, S., Li, Q., and Jiang, H. (2019). Association of blood pressure variability and intima-media thickness with white matter hyperintensities in hypertensive patients. *Front. Aging Neurosci.* 11:192. doi: 10.3389/fnagi.2019.00192

Choi, P., Ren, M., Phan, T. G., Calissaya, M., Ly, J. V., Beare, R., et al. (2012). Silent infarcts and cerebral microbleeds modify the associations of white matter lesions with gait and postural stability: population-based study. *Stroke* 43, 1505–1510. doi: 10.1161/STROKEAHA.111.647271

Chung, E., Lee, B. H., and Hwang, S. (2014). Core stabilization exercise with real-time feedback for chronic hemiparetic stroke: a pilot randomized controlled trials. *Restor. Neurol. Neurosci.* 32, 313–321. doi: 10.3233/RNN-130353

Chung, S. I., Yoo, H. S., Shin, N. Y., Park, Y. W., Lee, H. S., Hong, J. M., et al. (2021). Perivascular spaces in the basal ganglia and long-term motor prognosis in newly diagnosed Parkinson disease. *Neurology* 96, e2121–e2131. doi: 10.1212/WNLI.00000000001797

Clemson, L., Kendig, H., Mackenzie, L., and Browning, C. (2015). Predictors of injurious falls and fear of falling differ: an 11-year longitudinal study of incident events in older people. *J. Aging Health* 27, 239–256. doi: 10.1177/08982641456716

Cordonnier, C., Al-Shahi Salman, R., and Wardlaw, J. (2007). Spontaneous brain microbleeds: systematic review, subgroup analyses and standards for study design and reporting. *Brain* 130, 1988–2003. doi: 10.1093/brain/awl387

Davies, A. L., Desai, R. A., Bloomsfield, P. S., McIntosh, P. R., Chapple, K. J., Linnington, C., et al. (2013). Neurological deficits caused by tissue hypoxia in neuroinflammatory disease. *Ann. Neurol.* 74, 815–825. doi: 10.1002/ana.24006

de Laat, K. F., van den Berg, H. A., van Norden, A. G., Gons, R. A., Olde Rikkert, M. G., and de Leeuw, F. E. (2011). Microbleeds are independently related to gait disturbances in elderly individuals with cerebral small vessel disease. *Stroke* 42, 494–497. doi: 10.1161/STROKEAHA.110.596122

de Laat, K. F., van Norden, A. G., Gons, R. A., van Oudheusden, L. J., van Uden, I. W., Bloem, B. R., et al. (2010). Gait in elderly with cerebral small vessel disease. *Stroke* 41, 1652–1658. doi: 10.1161/STROKEAHA.110.583229

de Leeuw, F. E., de Groot, J. C., Achten, E., Oudkerk, M., Ramos, L. M., Heijboer, R., et al. (2001). Prevalence of cerebral white matter lesions in elderly people: a population based magnetic resonance imaging study. *The rotterdam scan study. J. Neurol. Neurosurg. Psychiatry* 70, 9–14. doi: 10.1136/jnnp.70.1.9

De Virgilio, A., Greco, A., Fabbrini, G., Inghilleri, M., Rizzo, M. L., Gallo, A., et al. (2016). Parkinson’s disease: autoimmunity and neuroinflammation. *Autoimmun. Rev.* 15, 1005–1011. doi: 10.1016/j.autrev.2016.07.022

Debette, S., and Markus, H. S. (2010). The clinical importance of white matter hyperintensities on brain magnetic resonance imaging: systematic review and meta-analysis. *BMJ* 341:c6666. doi: 10.1136/bmj.c6666

Desai, R. A., Davies, A. L., Tachrount, M., Kasti, M., Laulund, F., Golay, X., et al. (2016). Cause and prevention of demyelination in a model multiple sclerosis lesion. *Ann. Neurol.* 79, 591–604. doi: 10.1002/ana.24607

Dichgans, M., Markes, H. S., Salloway, S., Verkumnii, A., Moline, M., Wang, Q., et al. (2008). Donepezil in patients with subcortical vascular cognitive impairment: a randomised double-blind trial in CADASIL. *Lancet Neurol.* 7, 310–318. doi: 10.1016/S1474-4422(08)70046-2

Ding, J., Sigurdsson, S., Garcia, M., Phillips, C. L., Eiriksdottir, G., Gudmason, V., et al. (2015). Risk factors associated with incident cerebral microbleeds according to location in older people: the age, gene/environment susceptibility (AGES)-reykjavik study. *JAMA Neurol.* 72, 682–688. doi: 10.1001/jamaneurol.2015.0174

Downs, S. (2015). The berg balance scale. *J. Physiother.* 61:46. doi: 10.1016/j.jphys.2014.10.002

Erdos, B., Snipes, J. A., Tulbert, C. D., Katakam, P., Miller, A. W., and Busija, D. W. (2006). Rosuvastatin improves cerebrovascular function in Zucker obese rats by inhibiting NAD(P)H oxidase-dependent superoxide production. *Am. J. Physiol. Heart Circ. Physiol.* 290, H1264–1270. doi: 10.1152/ajpheart.00804.2005

Erdos, T., Happel, T., Kurz, A., Gauthier, S., Bullock, R., Lilienfeld, S., and Damaraju, C. V. (2002). Efficacy of galantamine in probable vascular dementia and Alzheimer’s disease combined with cerebrovascular disease: a randomised trial. *Lancet* 359, 1283–1290. doi: 10.1016/S0140-6736(02)08267-3
Dizziness and unstable gait in old age: etiology, diagnosis and treatment. *Disch. Arztebl. Int.* 112, 387–393. doi: 10.3389/arztebl.2015.0387

Jang, S. H. (2009). A review of corticospinal tract location at corona radiata and posterior limb of the internal capsule in human brain. NeuroRehabilitation 24, 279–283. doi: 10.3233/NRE:2009-0479

Kato-Navita, E. M., Nittrini, R., and Radanovic, M. (2011). Assessment of balance in mild and moderate stages of Alzheimer’s disease: implications on falls and functional capacity. *Argq. Neuropsiquiatr.* 69, 202–207. doi: 10.1590/S0044-282x2011000200012

Kester, M. I., Goos, J. D., Teunissen, C. E., Benedictus, M. R., Bouwman, F. H., Wijttes, M. P., et al. (2014). Associations between cerebral small-vessel disease and Alzheimer disease pathology as measured by cerebrospinal fluid biomarkers. *JAMA Neurol.* 71, 855–862. doi: 10.1001/jamaneurol.2014.754

Kim, H. W., Hong, J., and Jeon, J. C. (2020). Cerebral small vessel disease and Alzheimer’s disease: a review. *Front. Neurol.* 11:927. doi: 10.3389/fneur.2020.00927

Kim, Y. J., Kwon, H. K., Lee, J. M., Cho, H., Kim, H. J., Park, H. K., et al. (2016). Gray and white matter changes linking cerebral small vessel disease to gait disturbances. *Neurology* 86, 1199–1207. doi: 10.1212/WNL.0000000000002516

Kim, B. J., Kwon, S. U., Park, J. H., Kim, Y. J., Hong, K. S., Wong, L. K. S., et al. (2020). Cilostazol versus aspirin in ischemic stroke patients with high-risk cerebral hemorrhage: subgroup analysis of the PICASSO trial. *Stroke* 51, 931–937. doi: 10.1177/1059711119823855

Kim, J. H., Park, J., Kim, Y. H., Ma, H. L., and Kim, Y. J. (2015). Characterization of cerebral microbleeds in idiopathic Parkinson’s disease. *Eur. J. Neurosci.* 22, 377–383. doi: 10.1111/ejn.12584

Kopke, S., and Meyer, G. (2006). The Tinetti test: babylon in geriatric assessment. *Z. Gerontol. Geriatr.* 39, 288–291. doi: 10.1007/s00391-006-0398-y

Kwee, R. M., and Kwee, T. C. (2007). Virchow-Robin spaces at MR imaging. *Radiographics* 27, 1071–1086. doi: 10.1148/rg.27065722

La Vitol, P., Balducci, C., Cerovic, M., Santamaria, G., Brandi, E., Grandi, F., et al. (2018). Alpha-synuclein oligomers impair memory through glial cell activation and via Toll-like receptor 2. *Brain Behav. Immun.* 69, 591–602. doi: 10.1016/j.bbi.2018.02.012

Lassmann, H., Bruck, W., and Lucchetti, C. F. (2007). The immunopathology of multiple sclerosis: an overview. *Brain Pathol.* 17, 210–218. doi: 10.1111/j.1750-3639.2007.00064.x

Lauretani, F., Ticinesi, A., Giontii, L., Prati, B., Bouvengene, A., Tana, C., et al. (2019). Short-physical performance battery (SPPB) score is associated with falls in older outpatients. *Aging Clin. Exp. Res.* 31, 1435–1444. doi: 10.1007/s40520-018-1082-y

Lavretsky, H., Reinlieb, M., St Cyn, N., Siddarth, P., Ercoli, L. M., and Lavretsky, H., Reinlieb, M., St Cyn, N., Siddarth, P., Ercoli, L. M., and Lavretsky, H. (2014). Cerebral microbleeds: a biomarker of white matter injury. *Arch. Neurol.* 71, 561–569. doi: 10.1001/archneur.2014.754

Lee, J. S., Kim, J. S., Lee, K. S., An, J. Y., Kim, W., Kim, Y. I., et al. (2009). The severity of leukoaraiosis correlates with the clinical phenotype of Parkinson’s disease. *Arch. Gerontol. Geriatr.* 49, 255–259. doi: 10.1016/j.archger.2008.09.005

Lei, C., Liu, S., Rao, T., Hao, Z., Liu, M., and Wu, B. (2013). Association between cerebral microbleeds and cognitive function: a systematic review. *J. Neurol. Neurosurg. Psychiatry* 84, 693–697. doi: 10.1136/jnnp-2012-303948

Lenart, N., Broudh, D., and Denev, A. (2016). Inflammassomes link vascular disease with neuroinflammation and brain disorders. *J. Cereb. Blood Flow Metab.* 36, 1668–1675. doi: 10.1038/jcbfm.2016.204

Li, Q., Yang, Y., Reis, C., Tso, T., Li, W., Li, X., et al. (2018). Cerebral small vessel disease. *Cell Transplant.* 27, 1711–1722. doi: 10.1080/096369718795148

Lima, C. A., Ricci, N. A., Nogueira, E. C., and Perracini, M. R. (2018). The berg balance scale as a clinical screening tool to predict fall risk in older adults: a systematic review. *Physiotherapy* 104, 383–394. doi: 10.1016/j.physio.2018.02.002

Liu, Y., Braidy, N., Poljak, A., Chan, D. K. Y., and Sachdev, P. (2018). Cerebral small vessel disease and the risk of Alzheimer’s disease: a systematic review. *Ageing Res. Rev.* 47, 41–48. doi: 10.1016/j.arr.2018.06.002
Simpson, J. E., Fernando, M. S., Clark, I., Ince, P. G., Matthews, F., Forster, G., et al. (2007). White matter lesions in an unselected cohort of the elderly: astrocytic, microglial and oligodenodcyte precursor cell responses. Neuroradiol. Appl. Neurobiol. 33, 410–419. doi:10.1111/j.1365-2990.2007.00828.x

Smith, K. R., Kahlon, C. H., Brown, J. N., and Britt, R. B. (2021). Methylphenidate use in geriatric depression: a systematic review. Int. J. Geriatr. Psychiatry. 36, 1304–1312. doi:10.1002/gps.5536

Smith, E. E., O’Donnell, M., Dagenais, G., Lear, S. A., Wielgosz, A., Sharma, M., et al. (2015). Early cerebral small vessel disease and brain volume, cognition and gait. Ann. Neurol. 77, 251–261. doi:10.1002/ana.24320

Song, I. U., Lee, J. E., Kwon, D. Y., Park, J. H., and Ma, H. I. (2017). Parkinson’s disease might increase the risk of cerebral ischemic lesions. Int. J. Med. Sci. 14, 319–322. doi:10.7150/ims.18025

SPS3 Study Group, Benavente, O. R., Coffey, C. S., Conwit, R., Hart, R. G., McClure, L. A., et al. (2013). Blood-pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial. Lancet 382, 957–955. doi:10.1016/S0140-6736(13)60852-1

Srikanth, V., Phan, T. G., Chen, J., Beare, R., Stapleton, J. M., and Reutens, D. C. (2021). Motor system-related changes in limb oscillations are associated with gait and balance in preclinical Alzheimer’s disease: a pilot study. Neurobiol. Aging. 99, 1056112.

van den Berg, H. A., de Laat, K. F., Gons, R. A., van Dijk, E. J., and de Leeuw, F. E. (2011). Frontal and temporal microbleeds are related to cognitive function: the radboud university nijmegen diffusion tensor and magnetic resonance cohort (RUN DMC) study. Stroke 42, 3382–3386. doi:10.1161/STROKEAHA.111.269364

van Roosten, S., Goos, J. D., van Ospat, A. M., Versluis, M. J., Webb, A. G., Blauw, G. J., et al. (2014). Increased number of microinfarcts in Alzheimer disease at 7-T MR imaging. Radiology 270, 205–211. doi:10.1148/radiol.1310374

Verghe, J., Ayers, E., Barzilai, N., Bennett, D. A., Buchman, A. S., Holtzer, R., et al. (2014). Motoric cognitive risk syndrome: multicenter incidence study. Neurology 83, 2278–2284. doi:10.1212/WNL.00000000000001684

Vermeer, S. E., Longstreth, W. T., Jr., and Koudstaal, P. J. (2007). Silent brain infarcts: a systematic review. Lancet Neurol. 6, 611–619. doi:10.1016/S1474-4422(07)70170-9

Vinters, H. V. (2015). Emerging concepts in Alzheimer’s disease. Annu. Rev. Pathol. 10, 291–319. doi:10.1146/annurev-pathol-020712-163927

Volpato, S., Cavalleri, M., Siolus, F., Guerra, G., Maraldi, C., Zuliani, G., et al. (2011). Predictive value of the short physical performance battery following hospitalization in older patients. J. Gerontol. A Biol. Sci. Med. Sci. 66, 89–96. doi:10.1093/gerona/glq167

Wan, Y., Hu, W., Gan, J., Song, L., Wu, N., Chen, Y., et al. (2019). Exploring the association between Cerebral small-vessel diseases and motor symptoms in Parkinson’s disease. Brain Behav. 9:e01219. doi:10.1002/brb3.1219

Wang, N., Allali, G., Kesavadas, C., Noone, M. L., Pradeep, V. G., Blumen, H. M., et al. (2016). Cerebral small vessel disease and motoric cognitive risk syndrome: results from the kerala–einstein study. J. Alzheimers Dis. 50, 699–707. doi:10.3233/JAD-150523

Wardlaw, J. M., Smith, C., and Dichgans, M. (2013). Mechanisms of sporadic cerebral small vessel disease: insights from neuroimaging. Lancet Neurol. 12, 483–497. doi:10.1016/S1474-4422(13)70060-7

Wardlaw, J. M., Smith, E. E., Biessels, G. J., Cordonnier, C., Fazekas, F., Frayne, R., et al. (2013b). Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol. 12, 822–838. doi:10.1016/S1474-4422(13)70124-8

Webb, A. I., Fischer, U., Mehta, Z., and Rothwell, P. M. (2010). Effects of antihypertensive-drug class on interindividual variation in blood pressure and risk of stroke: a systematic review and meta-analysis. Lancet 375, 906–915. doi:10.1016/S0140-6736(10)60235-8

Wei, T. S., Liu, P. T., Chang, I. W., and Liu, S. Y. (2017). Gait asymmetry, ankle spasticity and depression as independent predictors of falls in ambulatory stroke patients. PLoS One 12:e0177136. doi:10.1371/journal.pone.0177136

Welch, S. A., Ward, R. E., Beauchamp, M. K., Leveille, S. G., Trivison, T., and Bean, J. F. (2021). The short physical performance battery (SPPB): a quick and useful tool for fall risk stratification among older primary care patients. J. Am. Med. Dir. Assoc. 22, 1646–1651. doi:10.1016/j.jamda.2020.09.038

Wennie Huang, W. N., Perera, S., VanSwearingen, J., and Studenski, S. (2010). Performance measures predict onset of activity of daily living difficulty in community-dwelling older adults. J. Am. Geriatr. Soc. 58, 844–852. doi:10.1111/j.1532-5415.2010.02820.x

Wu, Y. Z., Lin, J. Y., Wu, P. L., and Kuo, Y. F. (2019). Effects of a hybrid intervention combining exergaming and physical therapy among older adults in a long-term care facility. Geriatr. Gerontol. Int. 19, 147–152. doi:10.1111/ggi.13575

Xiong, Y., Wong, A., Cavalleri, M., Schmidt, R., Chu, W. W., Liu, X., et al. (2014). Prestroke statistics, progression of white matter hyperintensities and cognitive decline in stroke patients with confluent white matter hyperintensities. Neurotherapeutics 11, 606–611. doi:10.1007/s13311-014-0270-5

Yakushiji, Y., Nishiyama, M., Yakushiji, S., Hirotsu, T., Uchino, A., Nakajima, J., et al. (2009). Brain microbleeds and global cognitive function in adults without neurologic disorder. Stroke 39, 3323–3328. doi:10.1161/STROKEAHA.108.516112
Ye, S., Dong, S., Tan, J., Chen, L., Yang, H., Chen, Y., et al. (2019). White-matter hyperintensities and lacunar infarcts are associated with an increased risk of Alzheimer’s disease in the elderly in China. J. Clin. Neurol. 15, 46–53. doi: 10.3988/jcn.2019.15.1.46

Yip, J. L., Khawaja, A. P., Broadway, D., Luben, R., Hayat, S., Dalzell, N., et al. (2014). Visual acuity, self-reported vision and falls in the EPIC-Norfolk eye study. Br. J. Ophthalmol. 98, 377–382. doi: 10.1136/bjophthalmol-2013-304179

You, H., Zhang, H., Liu, J., Han, T., Zhang, M., Zhao, W., et al. (2017). Effect of balance training with pro-kin system on balance in patients with white matter lesions. Medicine (Baltimore) 96:e9057. doi: 10.1097/MD.00000000000009057

Zhang, C., Chen, Q., Wang, Y., Zhao, X., Wang, C., Liu, L., et al. (2014). Risk factors of dilated virchow-robin spaces are different in various brain regions. PLoS One 9:e105505. doi: 10.1371/journal.pone.0105505

Zhang, H., Cui, Y., Zhao, Y., Dong, Y., Wang, J., Duan, D., et al. (2019a). Association of circadian rhythm of blood pressure and cerebral small vessel disease in community-based elderly population. J. Gerontol. A Biol. Sci. Med. Sci. 74, 1322–1330. doi: 10.1093/gerona/gly212

Zhang, H., Cui, Y., Zhao, Y., Dong, Y., Duan, D., Wang, J., et al. (2019b). Effects of sartans and low-dose statins on cerebral white matter hyperintensities and cognitive function in older patients with hypertension: a randomized, double-blind and placebo-controlled clinical trial. Hypertens. Res. 42, 717–729. doi: 10.1038/s41440-018-0165-7

Zhang, J., Liu, N., and Yang, C. (2019). Effects of rosuvastatin in combination with nimodipine in patients with mild cognitive impairment caused by cerebral small vessel disease. Panminerva Med. 61, 439–443. doi: 10.23736/S0031-0808.18.03475-4

Zhang, G., Zhang, Y., Zhang, C., Wang, Y., Ma, G., Nie, K., et al. (2016). Striatal silent lacunar infarction is associated with changes to the substantia nigra in patients with early-stage Parkinson’s disease: a diffusion kurtosis imaging study. J. Clin. Neurosci. 33, 138–141. doi: 10.1016/j.jocn.2016.03.032

Zhao, W., You, H., Jiang, S., Zhang, H., Yang, Y., and Zhang, M. (2019). Effect of Pro-kin visual feedback balance training system on gait stability in patients with cerebral small vessel disease. Medicine (Baltimore) 98:e14503. doi: 10.1097/MD.0000000000014503

Zhou, X., Zhang, C., Li, L., Zhang, Y., Zhang, W., Yin, W., et al. (2020). Altered brain function in cerebral small vessel disease patients with gait disorders: a resting-state functional MRI study. Front. Aging Neurosci. 12:234. doi: 10.3389/fnagi.2020.00234

Zhu, Y. C., Tzourio, C., Soumare, A., Mazoyer, B., Dufouil, C., and Chabriat, H. (2010). Severity of dilated virchow-robin spaces is associated with age, blood pressure and MRI markers of small vessel disease: a population-based study. Stroke 41, 2483–2490. doi: 10.1161/STROKEAHA.110.591586

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Su, Yang, Wei and Zhao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.